Clinical Trials Logo

Retinal Perforations clinical trials

View clinical trials related to Retinal Perforations.

Filter by:

NCT ID: NCT06441656 Completed - Hacular Hole Repair Clinical Trials

The (Flip and Fix) Internal Limiting Flap Technique Versus the Classic Temporal Flap for Macular Hole Repair

Flip and Fix
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Purpose To describe a novel technique of MH repair and compare it to the perfluorocarbon liquid (PFCL) assisted temporal ILM flap technique. Methods Twenty-two eyes of 22 patients with MH were randomized on 1:1 basis into two groups. Group A cases were treated using the (Flip and Fix) technique in which the single-layer ILM flap was (flipped), flattened over the macula using PFCL and (fixed) in place using 2 drops of autologous non-heparinized blood over the superonasal and the inferonasal edges of the flap (away from the MH center). Group B patients had the classic temporal ILM flap technique without using the PFCL or autologous blood. All patients were followed up for a period of 6 months after the surgery. Results No significant difference was observed in initial and final visual acuities between Groups A and B. Intraoperative flap displacement and did not occur in Group A and occurred in 2 eyes in Group B (18.2%) one of them showed failed MH closure and required reoperation, These 2 cases had a final (W shape) MH closure and a worse final vision than the remaining cases which had either (U shape) or (V shape) final MH closure. Conclusions The study results show that the (Flip and Fix) technique is as effective as the PFCL-assisted temporal ILM flap technique and is associated with less ILM flap displacement risk for the repair of macular holes.

NCT ID: NCT06433284 Not yet recruiting - Macular Holes Clinical Trials

Comparative Study of Decellularized Human Amniotic Membrane Hydrogel and Inverted Internal Limiting Membrane Flap in Idiopathic Large Macular Holes

MACROHOLE
Start date: January 1, 2025
Phase: N/A
Study type: Interventional

The human amniotic membrane (hAM) patch, introduced by Rizzo et al. in 2018, showed a 100% anatomical success rate for large or failed macular holes over a 6-month follow-up. Despite its regenerative properties like promoting angiogenesis and having low immunogenicity, its clinical use is limited by challenges such as trimming to fit small holes and complications during insertion. To overcome these issues, decellularized amniotic membrane (dAM) has been processed into a hydrogel form, enhancing its applicability and allowing it to be used as an injectable hydrogel for minimally invasive therapies. While dAM hydrogels have been used in various medical fields, their application in intraocular surgery is new. This study proposes using dAM hydrogel for large macular hole closure, comparing its effectiveness to the inverted ILM flap technique in a randomized controlled trial.

NCT ID: NCT06359548 Recruiting - Macular Holes Clinical Trials

PEELED INTERNAL LIMITING MEMBRANE REPOSITION

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

Macular hiatus (MH) refers to a tissue defect in the photoreceptor cell layer of the inner boundary membrane of the optic disc in the macular region. Among them, idiopathic macular hiatus (IMH) is more common in people over 60 years old and is a common eye disease. With the aging of society, the number of patients increases, and it severely damages the patients' vision and life quality. Previously, the conventional surgical approach for treating MH was vitrectomy combined with inner limiting membrane (ILM) peeling. Although the closure rate of MH is high, many damages to the morphology and function of the ILM peeled area have been found. Our team firstly report a novel technique of peeled ILM reposition. Compared to traditional ILM peeling, the novel technique peeled ILM reposition maintains the integrity of internal retina by "pull" back the ILM flap. The previous pilot clinical study suggests that the novel technique peeled ILM reposition surgical intervention can achieve better morphology and functional prognosis. However, there is currently a lack of larger sample size prospective randomized controlled studies to further clarify the clinical efficacy of this new surgical technique in treating IMH. This study aims to conduct a single center, prospective, and randomized controlled study, combined with previous work, to analyze the efficacy of this novel technique peeled ILM peeling in the treatment of IMH. We hypothesize that this novel technique can achieved better morphological and functional prognosis compared to traditional ILM peeling.

NCT ID: NCT06323902 Completed - Macular Holes Clinical Trials

Autologous Platelet-rich Plasma as a Treatment for Macular Holes

Start date: October 25, 2022
Phase:
Study type: Observational

For a series of patients with full-thickness macular hole, an autologous plasma rich in growth factors was developed in the form of a clot and applied to the retinal defect. These patients were followed up for a period of one year, obtaining substantial improvement both anatomically and functionally.

NCT ID: NCT06233500 Recruiting - Macular Holes Clinical Trials

Macular Micro Vascular Changes Following Macular Hole Repair : Optical Coherence Tomography Angiography Study

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

The goal of this prospective interventional study is to to compare the micro vascular and structural changes between surgery with and without ILM flap to repair macular hole. The main questions it aims to answer are: - What are the macular micro vascular and structural changes pre and post repair of idiopathic full thickness macular hole and what is the correlation between these changes and visual recovery. - Is there are any prognostic values of the micro vascular status of the macula could be assessed preoperatively. - What are the differences regarding these micro vascular and structural changes between repair with and without ILM flap. Participants will be: - Subjected to pars plana vitrectomy to repair macular hole. - Examined by optical coherence tomography angiography pre and post operative Researchers will compare: Group A: eyes treated without ILM flap Group B : eyes treated by ILM flap to see if there are differences regarding the micro vascular and structural changes in the macular area.

NCT ID: NCT06211907 Not yet recruiting - Macular Holes Clinical Trials

Small Macular Holes Treated With Air

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

Non-inferiority trial comparing intraocular air and gas tamponade for closure of macular holes.

NCT ID: NCT06200727 Active, not recruiting - Glaucoma Clinical Trials

Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to observe the role of PRF in treating ophthalmic diseases.The efficacy and safety of PRF were validated for four ophthalmic conditions: macular hole, pterygium, corneal ulcer, and patients undergoing trabeculectomy for glaucoma. The main question aims to answer is PRF's effectiveness in ocular surface and fundus diseases. Participants will be divided into 2 groups, the experimental group will be treated with PRF and the control group will be treated with conventional surgery, with a 12-month postoperative follow-up to determine the role of PRF on wound healing in ophthalmic diseases.

NCT ID: NCT06194760 Active, not recruiting - Retinal Detachment Clinical Trials

Evaluation of Vitrectomy With ILM Peeling in Myopic Macular Hole With Only Posterior Retinal Detachment

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Retinal detachment (RD) resulting from the macular hole (MH), also known as MH-induced RD (MHRD), most commonly occurs in eyes with high myopia and results in irreversible visual disorders. Although ILM peeling for MHRD reportedly achieves a high retinal reattachment rate that ranges from 70% to 100%, the MH closure rate is relatively low, ranging from 10% to 70%.

NCT ID: NCT06115005 Recruiting - Macular Holes Clinical Trials

Treatment of Challenging Macular Holes Using Plasma Rich in Growth Factors

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

Aim of the Study:To report the structural and visual outcomes of plasma rich in growth factors in closure of challenging macular holes

NCT ID: NCT06079593 Not yet recruiting - Macular Holes Clinical Trials

GaslEss Macular Hole Surgery

GEM
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Macular holes are a hole in the centre of the retina, the light-sensing layer in the back of the eye. They cause a central 'blind spot' in the vision, which can be very disabling for patients. Standard surgery involves injecting a large gas bubble inside the eye. This takes 4-8 weeks to leave the eye. During this time vision is greatly reduced in the eye. This limits patients' ability to drive and work. Gas causes clouding of the natural lens in the eye (cataract). The gas can also raise pressure inside the eye, causing pain and sometimes loss of vision. Patients cannot fly or have certain medicines until the gas absorbs. Critically, most patients position face down for 50 minutes out of every hour for a week after surgery. This is to float the gas bubble onto the macula. Head positioning is particularly difficult. It very often causes pain in the neck, back, arms and legs. Rarely, blood clots can form in the legs and be life-threatening if they dislodge and travel to the lungs. Head positioning also places a large burden on those caring for the patient. The gases are 'greenhouse' gases and cause damage to the environment, for about 3,200 years. This study looks at a new surgical technique for treating macular holes. The new technique aims to make patients' recovery from surgery easier, and safer. The purpose of this study therefore is to compare two treatments: - Standard macular hole surgery with gas tamponade - Novel macular hole surgery without tamponade Gathering feasibility data to inform a future fully powered trial